Oncology

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

The senior director of the Clinical Trial Support Center at Blood Cancer United explains how nurse navigators help patients reach a 20% trial enrollment rate.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.